NCT03583528Active, not recruiting
DOTATOC PET/CT for Imaging NET Patients
Evaluation of the Safety and Sensitivity of 68Ga-DOTATOC PET/CT for Imaging NET Patients
Source: ClinicalTrials.gov · Last updated 12 May 2026
Brief summary (registry, in English)
Neuroendocrine tumours (NETs) are generally slow growing, but some can be aggressive and resistant to treatment. Compared to healthy cells, the surface of these tumor cells has a greater number of special molecules called somatostatin receptors (SSTR). Somatostatin receptor scintigraphy and conventional imaging are used to detect NETs. This study proposes 68Gallium(68Ga)-DOTATOC positron emission tomography/computed tomography (PET/CT) is superior to current imaging techniques. The goal is to evaluate the safety and sensitivity of 68Ga-DOTATOC PET/CT at detecting NETs and other tumors with over-expression of somatostatin receptors.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 8 Jun 2018
- Start date
- 11 Jul 2018
- Primary completion date
- 30 Sept 2026
- Lead sponsor
- British Columbia Cancer Agency
- Diseases
- Neuroblastoma, Neuroendocrine tumours, Lung cancer
- NCT number
- NCT03583528
What you commit to
- Study type: Observational
- Planned participants: 800
- From 11 Jul 2018 to the primary completion date, 30 Sept 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients who are medically unstable ex: acute cardiac or respiratory distress, hypotensive
Other
- Pregnancy
- Patients who exceed the safe weight limit of the PET/CT bed (204.5 kg) or who cannot fit through the PET/CT bore (diameter 70cm).
Who the study is looking for
- All subjects:
- World health organization performance status 0-2
- Able to provide written informed consent/assent (or consent by guardian for subjects \<19 years)
- Patients must be able to tolerate the physical/logistical requirements of completing a PET scan including lying flat for up to 30 minutes and tolerating intravenous cannulation for injection.
- Patients must require imaging for either staging or re-staging of:
- Gastroenteropancreatic tumors (e.g. carcinoids, gastrinoma, insulinoma, glucagonoma, VIPoma, etc.), functioning and non-functioning
- Sympathoadrenal system tumors (phaeochromocytoma, paraganglioma, neuroblastoma, ganglioneuroma)
- Medullary thyroid carcinoma
- Pituitary adenoma
- Medulloblastoma
- Merkel cell carcinoma
- Small-cell lung cancer (mainly primary tumors)
- Meningioma
- Or any other NET / with potential for overexpression of SSTR
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| BC Cancer Coordinator of this site? Confirm its status | Vancouver | Canada | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.